These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 17415548

  • 1. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
    Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P.
    Diabetologia; 2007 Jun; 50(6):1277-87. PubMed ID: 17415548
    [Abstract] [Full Text] [Related]

  • 2. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
    Bertram LS, Black D, Briner PH, Chatfield R, Cooke A, Fyfe MC, Murray PJ, Naud F, Nawano M, Procter MJ, Rakipovski G, Rasamison CM, Reynet C, Schofield KL, Shah VK, Spindler F, Taylor A, Turton R, Williams GM, Wong-Kai-In P, Yasuda K.
    J Med Chem; 2008 Jul 24; 51(14):4340-5. PubMed ID: 18588279
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY.
    Bioorg Med Chem; 2014 Apr 01; 22(7):2280-93. PubMed ID: 24588963
    [Abstract] [Full Text] [Related]

  • 4. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
    De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, Umbdenstock T, Vinson C, Combettes M, de Fanti B, Harley E, Sadlo M, Lefèvre AL, Broux O, Wierzbicki M, Fourquez JM, Perron-Sierra F, Kotschy A, Ktorza A.
    Br J Pharmacol; 2013 Jan 01; 168(2):339-53. PubMed ID: 22925001
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP.
    Mol Pharmacol; 2011 Dec 01; 80(6):1156-65. PubMed ID: 21937665
    [Abstract] [Full Text] [Related]

  • 6. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
    De Ceuninck F, Kargar C, Charton Y, Goldstein S, Perron-Sierra F, Ilic C, Caliez A, Rolin JO, Sadlo M, Harley E, Vinson C, Ktorza A.
    Br J Pharmacol; 2013 Jul 01; 169(5):999-1010. PubMed ID: 23488540
    [Abstract] [Full Text] [Related]

  • 7. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
    Baker DJ, Wilkinson GP, Atkinson AM, Jones HB, Coghlan M, Charles AD, Leighton B.
    Br J Pharmacol; 2014 Apr 01; 171(7):1642-54. PubMed ID: 24772484
    [Abstract] [Full Text] [Related]

  • 8. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.
    Futamura M, Yao J, Li X, Bergeron R, Tran JL, Zycband E, Woods J, Zhu Y, Shao Q, Maruki-Uchida H, Goto-Shimazaki H, Langdon RB, Erion MD, Eiki J, Zhou YP.
    Diabetologia; 2012 Apr 01; 55(4):1071-80. PubMed ID: 22234649
    [Abstract] [Full Text] [Related]

  • 9. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF.
    Science; 2003 Jul 18; 301(5631):370-3. PubMed ID: 12869762
    [Abstract] [Full Text] [Related]

  • 10. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
    Lei L, Liu S, Li Y, Song H, He L, Liu Q, Sun S, Li Y, Feng Z, Shen Z.
    Eur J Pharmacol; 2018 May 05; 826():17-23. PubMed ID: 29477658
    [Abstract] [Full Text] [Related]

  • 11. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
    Tsumura Y, Tsushima Y, Tamura A, Hasebe M, Kanou M, Kato H, Kobayashi T.
    PLoS One; 2017 May 05; 12(2):e0172252. PubMed ID: 28207836
    [Abstract] [Full Text] [Related]

  • 12. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
    Al-Oanzi ZH, Fountana S, Moonira T, Tudhope SJ, Petrie JL, Alshawi A, Patman G, Arden C, Reeves HL, Agius L.
    Diabetes Obes Metab; 2017 Aug 05; 19(8):1078-1087. PubMed ID: 28206714
    [Abstract] [Full Text] [Related]

  • 13. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
    Deshpande AM, Bhuniya D, De S, Dave B, Vyavahare VP, Kurhade SH, Kandalkar SR, Naik KP, Kobal BS, Kaduskar RD, Basu S, Jain V, Patil P, Chaturvedi Joshi S, Bhat G, Raje AA, Reddy S, Gundu J, Madgula V, Tambe S, Shitole P, Umrani D, Chugh A, Palle VP, Mookhtiar KA.
    Eur J Med Chem; 2017 Jun 16; 133():268-286. PubMed ID: 28390958
    [Abstract] [Full Text] [Related]

  • 14. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J, Lin S, Myers RW, Trujillo ME, Pachanski MJ, Malkani S, Chen HS, Chen Z, Campbell B, Eiermann GJ, Elowe N, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, McMasters DR, Mitra K, Tong X, Xu L, Zhang F, Zhang R, Addona GH, Berger JP, Zhang B, Parmee ER.
    Bioorg Med Chem Lett; 2017 May 01; 27(9):2063-2068. PubMed ID: 28284809
    [Abstract] [Full Text] [Related]

  • 15. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
    Dhanesha N, Joharapurkar A, Shah G, Kshirsagar S, Patel V, Patel K, Bahekar R, Jain M.
    Eur J Pharmacol; 2013 Aug 15; 714(1-3):188-92. PubMed ID: 23810686
    [Abstract] [Full Text] [Related]

  • 16. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator.
    Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ.
    Diabetes; 2007 Jun 15; 56(6):1694-702. PubMed ID: 17360975
    [Abstract] [Full Text] [Related]

  • 17. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells.
    Wei P, Shi M, Barnum S, Cho H, Carlson T, Fraser JD.
    Diabetologia; 2009 Oct 15; 52(10):2142-50. PubMed ID: 19641898
    [Abstract] [Full Text] [Related]

  • 18. Identification of a new class of glucokinase activators through structure-based design.
    Hinklin RJ, Boyd SA, Chicarelli MJ, Condroski KR, DeWolf WE, Lee PA, Lee W, Singh A, Thomas L, Voegtli WC, Williams L, Aicher TD.
    J Med Chem; 2013 Oct 10; 56(19):7669-78. PubMed ID: 24015910
    [Abstract] [Full Text] [Related]

  • 19. A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
    Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD, Giese U, Guo H, Radloff M, Gil GS, Sewing S, Wang Y, Weichert A, Zaliani A, Gromada J.
    Endocrinology; 2005 Sep 10; 146(9):3696-701. PubMed ID: 15919746
    [Abstract] [Full Text] [Related]

  • 20. Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats.
    Coope GJ, Atkinson AM, Allott C, McKerrecher D, Johnstone C, Pike KG, Holme PC, Vertigan H, Gill D, Coghlan MP, Leighton B.
    Br J Pharmacol; 2006 Oct 10; 149(3):328-35. PubMed ID: 16921397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.